This study aims to investigate the predictive role of neoadjuvant chemotherapy in patients with HER2-low BC clinicopathologic features, baseline and preoperative NLR,PLR,LMR and SII axillary pCR. The gene discussed is ERBB2; the disease is breast cancer.